Psoriasis and Comorbidities Psoriasis and Cardiometabolic Comorbidities.

Slides:

Advertisements

Similar presentations

Raptiva™ (efalizumab) Plaque Psoriasis: The Unmet Need

Advertisements

Gerald G Krueger MD Professor, Benning Presidential Endowed Chair

EXPRESS: Response Rates at Week Placebo (n=77) Infliximab 5 mg/kg (n=301) Per cent of patients Per cent of patients with.

C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.

1 Agenda  Overview –Burt Adelman MD  Efficacy and Pharmacodynamics –Akshay Vaishnaw MD, PhD  Safety –Gloria Vigliani MD  Alefacept Risk Benefit Profile.

STUDY 303 A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given.

Secukinumab Retreatment Shows Rapid Recapture of Treatment Response: An Analysis of a Phase 3 Extension Trial in Psoriasis

Difficult-to-Treat Psoriasis: Gaining Control of Palmoplantar and Nail Psoriasis.

Patients were considered not in MDA (MDA−) with a score of 0, 1, 2, 3 or 4 points and in MDA (MDA+) with a score of 5, 6 or 7 points.

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Psoriasis What’s New Dr. Vincent P Beltrani

Perspectives in Psoriasis: Assessing Treatment Efficacy—Which Measures, What Do They Tell Us?

Optimizing Quality of Life and Mental Health in Patients With Psoriasis.

From Conference to Practice: Big Data in Psoriasis

Biological Therapy in Psoriasis: Recognizing the Value

An Interprofessional Approach to the Patient With Chronic Airway Disease.

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis Zarif K. Jabbar-Lopez, Zenas Z.N. Yiu,

IL-17 Inhibitors in the Management of Psoriatic Disease

Efficacy of simvastatin in plaque psoriasis: A pilot study

NICE-BAD clinical audit on psoriasis

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

WORCESTERSHIRE PATHWAY for use of CYTOKINE MODULATORS in

Evolving Treatment Landscape for PsA

ADVANCED PARKINSON'S DISEASE:

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

New Recommendations on How to Stage Hidradenitis Suppurativa

New Data on Emerging Treatments for Psoriasis

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Improving Outcomes in Psoriatic Arthritis

Amy S. Paller, MD, Elaine C. Siegfried, MD, David M

Proportion of Patients Achieving a ≥30% Reduction in Pain Scores at Week 12 of Stable Dose Treatment

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

The Multifaceted Nature of Psoriasis Addressing Patients' Needs

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled.

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis Kristian Reich,

The Burden of Psoriasis:

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis Kenneth B. Gordon, Richard G. Langley,

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Dubai regional meeting

Research Techniques Made Simple: Network Meta-Analysis

EXPERT INSIGHTS: IL-17 INHIBITION IN PSORIASIS CARE

Essential Updates for PsA: A Complex Disease to Manage

Comment on “Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis” Kristian Reich, Craig Leonardi,

Module 5: Formulating Research Questions

OR for baseline predictors of MDA at weeks 12, 24, 48, 96 and 144 by univariate analysis of observed data. OR for baseline predictors of MDA at weeks 12,

Targeting IL-23 for Therapeutic Longevity in Psoriasis

Understanding How IL-23p19 Inhibitors Work in Psoriasis

Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort Elaine Kunzler, MD, Stephanie Florez-Pollack,

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Jennifer L. Hundley, MD, Christie L

Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial Alice Gottlieb, MD, PhD, John Sullivan,

Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase 3 trials.

Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial Boni E. Elewski, MD, Martin.

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Alan Menter, MD, Stephen K

An App Supporting Psoriasis Patients Improves Adherence to Topical Treatment: A randomised controlled trial M.T. Svendsen,1,2,3 F. Andersen,1,4 K.H. Andersen,4.

Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: A pooled analysis of the Phase 3 VOYAGE 1 and VOYAGE.

DAPSA LSM change from baseline (A), patients achieving DAPSA ≤28 (MDA) (B), DAPSA ≤14 (LDA) (C) or DAPSA ≤4 (REM) (D) after 24 weeks in patients treated.

Program. The Impact of Treatment Success and Failure in Psoriasis: Implications for Clinical Practice.

The percentage of patients with baseline BSA ≥ 3% in the ITT population who achieved (a) PASI 75, (c) PASI 90, and (e) PASI 100 during the 24-week double-blind.

Areas of Special Interest in PsO

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Psoriasis and Comorbidities

Psoriasis and Cardiometabolic Comorbidities

Physician’s Global Assessment (PGA)

Calculation of PASI

Absolute PASI Values (Cutoffs: 5, 3, or 2) Might Provide a Better Benchmark

Dermatology Life Quality Index (DLQI)

Some Thoughts on Psoriasis Disease Severity/Therapy Assessment Tools

Concept of Psoriasis Management

Improving Magnitude of Response: QoL Is Maximized in Patients Who Achieve PASI 90-100 Response

Significance of When Psoriasis Develops

Five Key Components to CLCI

Interaction of Key Interpersonal Components That Make Patients More or Less Vulnerable to CLCI

Does a More Aggressive Intervention Improve Psoriasis Patient Satisfaction

Effects of Stigmatization

Mismatch Between Patient and Physician Perspectives on Psoriasis

Greater disease severity & younger age  greater psychosocial burden Online survey, n=1033

MAPP Survey Results: Patient vs Physician on Contributors to Psoriasis Severity

Qualitative Research: Patient and Physician Interviews

Divergence in Patients' vs Physicians' Perspectives May Result in Suboptimal Treatment

A Holistic Approach to Treating Psoriasis

Building Trust; Improving Physician/Patient Communication

Secukinumab Efficacy Data Over 2 Years Randomized Extension of ERASURE and FIXTURE

UNCOVER-3: Study Design With Long-Term Extension

UNCOVER-3: Ixekizumab PASI 75 Response Rates to Week 60 (NRI)